Scientists from UNSW Sydney and the UK have discovered that the human immunodeficiency virus (HIV) hijacks a small molecule from the host cell to protect itself from being destroyed by the host's immune system.

The study shows that clinical interventions should take place at lower viral loads than those proposed by the current World Health Organization guidelines.

Vemlidy® is the first new treatment for chronic hepatitis B infection to be approved in the European Union in nearly a decade Gilead Sciences, Inc. (Nasdaq: GILD) announced that the European Commission has granted marketing authorization for Vemlidy® (tenofovir alafenamide, TAF) 25 mg, a once-daily tablet ...